app.medall.org/event-listings…

The efficacy and resistance-breaking potential of EPI-7386 masofaniten in castration-resistant #ProstateCancer . Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center joins Zach Klaassen Georgia Cancer Center discussing the continuous effort to refine hormonal therapy in #PCa management > bit.ly/3OM2CAD

Dual action hormone therapy targeting two parts of the androgen receptor simultaneously shows tolerability and early efficacy in phase I trial. Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center and Rana McKay UC San Diego discuss recent advancements in #mCRPC treatments > bit.ly/47JrY9N

‼️ This combination IIT for pts w refractory penile cancer supported by GSK US is accruing pts Moffitt Cancer Center Philippe spiess and soon at MD Anderson Cancer Center Curtis Pettaway, MD and USC Norris Comprehensive Cancer Center please offer this option to your pts and reach out w questions Global Society of Rare GU Tumors

Masofaniten Plus Enzalutamide Demonstrates Safety and Durable Responses in mCRPC Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center ESMO - Eur. Oncology #ESMO23 #pcsm onclive.com/view/masofanit…

We are pleased to announce the PCCTC-managed study of EPI-7386 in combination with enzalutamide in subjects with metastatic prostate cancer has entered phase 2. For more information visit: classic.clinicaltrials.gov/ct2/show/NCT05…

ADT interruption in patients responding exceptionally to AR-pathway inhibitor in #mHSPC : A-DREAM. Atish Choudhury, MD PhD and Alicia Morgans, MD, MPH Dana-Farber discuss the right balance of treatment duration for patients with metastatic prostate cancer > bit.ly/3NOBSOK

Andrew Laccetti, MD, MS, at Memorial Sloan Kettering Cancer Center underscores “to date, androgen receptor (AR) pathway inhibitors either competitively antagonize the receptor via the ligand-binding domain or block androgen synthesis.” ow.ly/s8NB50PZOWg Andy Laccetti MD, MS #ESMO23

Phase 1/2 Trial: Oral EPI-7386 + Enza vs Enza Alone in mCRPC: Ph 1 Results #ESMO23 UroToday.com Andy Laccetti MD, MS

📍To date, n=18
📍Safety: consistent w/ 2nd-gen antiandrogens
📍PK results: Enza minimally impacted by EPI-7386 --> full dose Enza (160 mg) in cohort 4
📍Evaluable data:…

Next-Generation Aniten Masofaniten Gains Momentum in mCRPC Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center #pcsm onclive.com/view/next-gene…

⭐️Unprecedented amount of PRACTICE CHANGING studies in GU oncology ESMO - Eur. Oncology this weekend. Looking forward to seeing these presentations from Bradley McGregor Toni Choueiri, MD Neeraj Agarwal, MD, FASCO Tom Powles Andrea Apolo, M.D. Oliver Sartor silke gillessen OncoAlert

Dates and times 👇

Happy ASCO #ASCOGI24 submission day to those who celebrate (late-breaking abstracters: this tweet does not apply to you)

We are hiring a Genitourinary Medical Oncologist to provide outstanding patient-centered care at our Monmouth Regional site in NJ. We are looking for either a clinical investigator or a clinician for this role. Join a great team! See ad for details.
careers.mskcc.org/vacancies/2023…

In this editorial, Susan F. Slovin, MD, PhD, reviews the recent trial by Daniel E Spratt et al. and discusses the prospects and limitations of applying an AI-based predictive model to guide treatment for prostate cancer.

#MedicalAI #PCSM #UroSoMe Memorial Sloan Kettering Cancer Center Sidney Kimmel Cancer Center – Jefferson Health

Been working on a mini-comic about cancer cachexia. Cancer cachexia can be one of the most emotionally-charged symptoms we work with in clinic, for patients AND families. #palliativecare #supponc #hapc #wip #graphicmedicine

Learn more about the phase 1/2 study of EPI-7386 in combination with enzalutamide compared with Enza alone in subjects with #mCRPC . Presented by Andy Laccetti MD, MS Memorial Sloan Kettering Cancer Center. Written coverage by Dr. Jones Nauseef Weill Cornell Medicine > bit.ly/3lJfxYJ

Debunking the myth of the weekend warrior risk.
Same cardiovascular benefit for ≥ 150 minutes of physical activity/week, irrespective of number of days
Patrick Ellinor Mass General Heart Shaan Khurshid
jamanetwork.com/journals/jama/… JAMA

Morgan Roupret Christopher Sweeney, MBBS European Association of Urology (EAU) European Urology Oncology Alberto Briganti Here the lessons!!

.Georges Gebrael, Nicolas Sayegh, MD & Umang Swami of Huntsman Cancer Institute unpack recent #ClinicalTrial data & answer the question: When would you use doublet therapy & not triplet therapy for a patient w/ newly diagnosed #mHSPC ? fal.cn/3zn9w #ASCODailyNews #GUCSM